Paper Details

  1. Home
  2. Paper Details

Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.

Author: CapriniJoseph A, ClemensAndreas, ErikssonBengt I, FriedmanRichard J, KurthAndreas, NoackHerbert

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.
Paper Details　
Original Abstract of the Article :
Patients undergoing total hip or knee arthroplasty should receive anticoagulant therapy because of the high risk of venous thromboembolism. However, many are already taking non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA) that can have antihaemostatic effects. We assessed...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1160/TH11-08-0589

データ提供：米国国立医学図書館（NLM）

Dabigatran Etexilate: A Safe Choice for Thromboprophylaxis in Joint Replacement

Patients undergoing total hip or knee replacement surgery are at high risk for blood clots, making anticoagulation therapy a crucial part of their care. However, many patients already take non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA), which can increase the risk of bleeding. This study investigates the safety of using dabigatran etexilate, a newer anticoagulant, in patients undergoing joint replacement surgery, both with and without concomitant NSAID or ASA use. The study found that dabigatran etexilate was associated with a similar risk of major bleeding events in patients taking NSAIDs or ASA compared to those not taking these medications. This reassuring finding suggests that dabigatran etexilate can be safely used for thromboprophylaxis in joint replacement patients, even those taking concomitant NSAIDs or ASA.

A Safe Oasis in the Desert of Anticoagulation

Dabigatran etexilate, like a reliable oasis in a desert, offers a safe and effective way to prevent blood clots in patients undergoing joint replacement surgery. The study's findings provide strong evidence for its safety, even when used in conjunction with NSAIDs or ASA, making it a valuable option for these patients.

Balancing the Scales: Safety and Effectiveness in Joint Replacement

This research highlights the importance of finding a balance between preventing blood clots and minimizing the risk of bleeding. Dabigatran etexilate, with its proven safety profile, provides a promising solution for achieving this delicate balance in patients undergoing joint replacement surgery.

Dr.Camel's Conclusion

Dabigatran etexilate, like a skilled camel guide navigating the treacherous sands of anticoagulation, offers a safe and effective solution for preventing blood clots in joint replacement patients, even those taking NSAIDs or ASA. This study provides valuable insights for healthcare providers, empowering them to make informed decisions about anticoagulation strategies.

Date :
  1. Date Completed 2012-11-12
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

22552763

DOI: Digital Object Identifier

10.1160/TH11-08-0589

Related Literature

Article Analysis
・Effects of dabigatran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.